Navigation Links
Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh
Date:1/5/2012

FREMONT, Calif., Jan. 5, 2012 /PRNewswire/ -- Biomerix Corporation announced today that it has received CE Mark approval  for its ASSURE soft tissue repair mesh, a novel composite mesh intended for the reconstruction of hernias and soft tissue deficiencies and for the temporary bridging of fascial defects.  This approval allows Biomerix to distribute ASSURE throughout Europe and support certification in many other parts of the world that recognize the CE Mark for commercial distribution purposes. 

ASSURE is constructed of three distinct layers, each layer providing an important function in the repair of a hernia or soft tissue deficiency.  The first layer consists of the Biomerix Biomaterial, a proprietary, biointegrative synthetic polyurethane tissue scaffold designed to play a role similar to that of the body's extracellular matrix, a biological structure that supports tissue repair and regeneration.  The second layer is a knitted polypropylene monofilament mesh which provides mechanical support for a strong, durable and flexible repair.  The third layer consists of a resorbable lactide caprolactone copolymer film designed to minimize tissue attachment to the device in case of direct contact with the viscera.

"ASSURE's distinctive multi-layered design reflects extensive market research to address patient comfort and surgeon ease-of-use in open and laparoscopic (minimally invasive) hernia repair procedures.  The device incorporates the unique properties of a biologic tissue scaffold to support tissue regeneration with the best properties of a synthetic biomaterial in terms of its strength and durability," said Kenneth G. Hayes, President and CEO of Biomerix Corporation.  "ASSURE is already available in the United States after receiving a 510(k) clearance from the U.S. Food and Drug Administration (FDA) in May 2010.  We are thrilled with the initial US experience to date and believe that ASSURE will provide substantial clinical benefits to patients."

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
2. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
3. Biomerix Awarded Two Device Licenses by Health Canada
4. Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
(Date:4/28/2017)... ... 28, 2017 , ... NuevaCare, a leading home care agency based in San ... Alto, is proud to announce information upgrades to its blog in the form of ... on topics such as home care (generally) as well as senior care and home ...
(Date:4/27/2017)... ... 2017 , ... The Incentive Research Foundation is pleased to ... a groundbreaking analysis of how behavioral economics can be applied to the incentive, ... programs, the report highlights proven behavioral economics approaches and the powerful role emotions ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
Breaking Medicine News(10 mins):